FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SARIN RAVI YANG (Last) (First) (Middle) C/O THE ONCOLOGY INSTITUTE INC. 18000 STUDEBAKER RD, SUITE 800 (Street)				Issuer Name and Ticker or Trading Symbol Oncology Institute, Inc. [TOI] Date of Earliest Transaction (Month/Day/Year) 11/12/2021 4. If Amendment, Date of Original Filed (Month/Day/Year)) 6	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person					
(City)			0703 Zip)											X Form filed by More than One Reporting Person				
		Table	I - N	on-Deriva	tive S	Se	curitie	s Ac	quire	d, Di	sposed of	, or E	Benefic	ially O	vned			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/North/Day/No			Execution Date,			n Date, Transa Code		action (Instr.						Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) (D)	or Price	Tran	ransaction(s) Instr. 3 and 4)		(o)				
Common Stock 11/12/20.)21			A		4,109,771	. A ⁽	1) \$0	4	4,109,771			See footnote ⁽²⁾			
		Tal	ole II								osed of, convertib				ned			
Derivative Conversion [Date Exec (Month/Day/Year) if an		eemed ution Date, th/Day/Year)	4. Transact Code (In 8)				Expiration E (Month/Day		ate	Amount of Securities S		8. Price Derivati Security (Instr. 5)	e derivati	ve es ally ng d tion(s)	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares					
	nd Address of	Reporting Person* ANG																
(Last)		(First)	(N	Middle)														

1. Name and Address of Reporting Person* <u>SARIN RAVI YANG</u>							
(Last)	(First)	(Middle)					
C/O THE ONCOL	OGY INSTITUTE I	INC.					
18000 STUDEBAKER RD, SUITE 800							
(Street) CERRITOS	CA	90703					
(City)	(State)	(Zip)					
1. Name and Address of OncologyCare							
(Last)	(First)	(Middle)					
10207 CLEMATIS	CT,						
(Street)							
LOS ANGELES,	CA	90077					
(City)	(State)	(Zip)					

Explanation of Responses:

- 1. Received in connection with the the business combination between DFP Healthcare Acqusitions Corp. and The Oncology Institute, Inc. (the "Business Combination").
- 2. Reflects shares owned by OncologyCare Partners, LLC. OncologyCare Holdings, LLC is the manager of OncologyCare Partners, LLC, and, Ravi Sarin serves as the managing member of OncologyCare Holdings, LLC. As a result, Mr. Sarin indirectly has the power to control OncologyCare Partners, LLC, and is deemed to have indirect beneficial ownership of the securities held by OncologyCare Partners, LLC.

By: /s/ Ravi Sarin, managing member

** Signature of Reporting Person

erson Date

11/16/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.